Moberg Pharma AB (FRA:MB8) Total Operating Expense: €3.06 Mil (TTM As of Mar. 2026)


FRA:MB8 Moberg Pharma AB FRA:MB8
60 GF Score
Price €0.80
GF Value €1.05
! 1 Warning Sign
View Full Analysis

What is Moberg Pharma AB Total Operating Expense?

Moberg Pharma AB FRA:MB8 +0.38% 60 Total Operating Expense is €3.06 Mil as of Mar. 2026. GuruFocus rates FRA:MB8 with a GF Score™ of 60/100 and a GF Value™ of €1.05. The stock has 1 warning sign investors should review.

Moberg Pharma AB's Total Operating Expense for the three months ended in Mar. 2026 was €0.48 Mil. Moberg Pharma AB's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €3.06 Mil.

Moberg Pharma AB Total Operating Expense Related Terms

Moberg Pharma AB Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Moberg Pharma AB's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moberg Pharma AB Total Operating Expense Chart

Moberg Pharma AB Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec21 Dec22 Dec23 Dec24
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.92 1.92 1.89 2.50 28.79

Moberg Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.61 1.04 0.77 0.78 0.48
FRA:MB8
60GF Score
Moberg Pharma AB FRA:MB8
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moberg Pharma AB Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €3.06 Mil mean?
Moberg Pharma AB (FRA:MB8) has a Total Operating Expense of €3.06 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Moberg Pharma AB and its competitors.
Is Moberg Pharma AB's Total Operating Expense too high?
Moberg Pharma AB's current Total Operating Expense is €3.06 Mil. Overall, Moberg Pharma AB has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's Total Operating Expense compare to ZTS and UTHR?
Moberg Pharma AB's Total Operating Expense of €3.06 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Moberg Pharma AB and its competitors. Moberg Pharma AB's current Total Operating Expense is €3.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Moberg Pharma AB (FRA:MB8) has a current Total Operating Expense of €3.06 Mil. The stock's GF Value™ is €1.05, compared to a current price of €0.80 — trading 24% below its estimated fair value. The current Total Operating Expense is €3.06 Mil. Moberg Pharma AB's overall GF Score™ is 60/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Moberg Pharma AB (FRA:MB8), the current Total Operating Expense is €3.06 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Moberg Pharma AB (FRA:MB8) Overvalued in 2026?

Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued. The current stock price of €0.80 is trading 24% below its estimated GF Value™ of €1.05.

Key valuation signals for FRA:MB8:

  • Total Operating Expense: €3.06 Mil
  • GF Value™: €1.05 vs. price of €0.80 (24% below fair value)
  • GF Score™: 60/100 with 1 warning sign

No single metric tells the full story. See the FRA:MB8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Moberg Pharma AB Business Description

Other Exchanges MBGPF:USAMOB:Sweden
Address Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
60GF Score

Get the complete analysis for FRA:MB8

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.80
Price
€1.05
GF Value